ES2054019T5 - Procedimiento para la purificacion de proteinas dependientes de la vitamina k. - Google Patents

Procedimiento para la purificacion de proteinas dependientes de la vitamina k.

Info

Publication number
ES2054019T5
ES2054019T5 ES89310061T ES89310061T ES2054019T5 ES 2054019 T5 ES2054019 T5 ES 2054019T5 ES 89310061 T ES89310061 T ES 89310061T ES 89310061 T ES89310061 T ES 89310061T ES 2054019 T5 ES2054019 T5 ES 2054019T5
Authority
ES
Spain
Prior art keywords
vitamin
proteins
purification
procedure
dependent proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89310061T
Other languages
English (en)
Other versions
ES2054019T3 (es
Inventor
Sau-Chi Betty Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26943089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2054019(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2054019T3 publication Critical patent/ES2054019T3/es
Application granted granted Critical
Publication of ES2054019T5 publication Critical patent/ES2054019T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

LA RECUPERACION DE PROTEINAS DEPENDIENTES DE LA VITAMINA K PRODUCIDAS POR MICROORGANISMOS TRANSFORMADOS PUEDEN EFECECTUARSE A PARTIR DE UN MEDIO DE CULTIVO DE CELULAS UTILIZANDO LOS CAMBIOS EN LA PROTEINA QUE OCURREN EN PRESENCIA DE CATIONES DIVALENTES PARA ALTERAR LA AFINIDAD DE ENLACE DE LAS PROTEINAS Y POR LO TANTO SEPARAR SELECTIVAMENTE LAS PROTEINAS DE LOS CONTAMINANTES EN EL MEDIO DE CULTIVO USANDO CROMATOLOGIA ESTANDAR.
ES89310061T 1988-10-04 1989-10-02 Procedimiento para la purificacion de proteinas dependientes de la vitamina k. Expired - Lifetime ES2054019T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327988A 1988-10-04 1988-10-04
US07/393,281 US4981952A (en) 1988-10-04 1989-08-16 Method for the purification of vitamin K-dependent proteins

Publications (2)

Publication Number Publication Date
ES2054019T3 ES2054019T3 (es) 1994-08-01
ES2054019T5 true ES2054019T5 (es) 2002-10-16

Family

ID=26943089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89310061T Expired - Lifetime ES2054019T5 (es) 1988-10-04 1989-10-02 Procedimiento para la purificacion de proteinas dependientes de la vitamina k.

Country Status (13)

Country Link
US (1) US4981952A (es)
EP (1) EP0363126B2 (es)
JP (1) JP2848461B2 (es)
KR (1) KR0139209B1 (es)
AT (1) ATE106406T1 (es)
AU (1) AU635222B2 (es)
CA (1) CA1314011C (es)
DE (1) DE68915675T3 (es)
DK (1) DK176090B1 (es)
ES (1) ES2054019T5 (es)
HU (1) HU204538B (es)
IE (1) IE63765B1 (es)
IL (1) IL91822A (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
DE3833936C1 (es) * 1988-10-05 1989-09-21 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
DE3911629A1 (de) * 1989-04-10 1990-10-11 Behringwerke Ag Verfahren zur abtrennung von toxinen aus proteinloesungen
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
JP3418621B2 (ja) * 1991-03-01 2003-06-23 アヴェンティス ベーリング エルエルシー Ｉｘ因子の調製
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
DE4406515C1 (de) * 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US5843731A (en) * 1996-09-05 1998-12-01 Asahi Kogaku Kogyo Kabushiki Kaisha Method for purifying plasmid DNA on calcium phosphate compound
US5910584A (en) * 1996-09-05 1999-06-08 Asahi Kogaku Kogyo Kabushiki Kaisha Method for isolating plasmid DNA
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1557463A1 (en) * 1997-04-28 2005-07-27 Eli Lilly & Company Improved methods for processing activated protein C
CA2293429A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
EP1124573A1 (en) 1998-10-22 2001-08-22 Eli Lilly And Company Methods for treating sepsis
EP1128842B1 (en) 1998-11-13 2006-03-15 Eli Lilly And Company Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia
WO2000030677A1 (en) 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
IL142247A0 (en) 1998-11-23 2002-03-10 Lilly Co Eli Method of treating sickle cell disease and thalassemia
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
CN1250567C (zh) * 2000-07-21 2006-04-12 财团法人化学及血清疗法研究所 钙离子结合蛋白的提纯方法
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
EP1417055A4 (en) * 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
JP4628618B2 (ja) * 2001-09-26 2011-02-09 富士フイルム株式会社 撮像光学系
CA2475738A1 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1651252B1 (en) * 2003-07-08 2014-11-26 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
EP1831242B1 (en) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
ES2349112T3 (es) * 2005-01-14 2010-12-28 Bayer Healthcare Llc Método de purificación de factor vii.
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
WO2007071767A1 (en) * 2005-12-23 2007-06-28 Novo Nordisk Health Care Ag Purification of vitamin k-dependent polypeptides using preparative reverse phase chromatography (rpc)
TWI428448B (zh) * 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
EP2078074A4 (en) * 2006-10-31 2011-09-28 Scripps Research Inst DOSAGE SCHEME OF ACTIVATED PROTEIN C AND ITS VARIANTS WITH REDUCED ANTICOAGULANT ACTIVITY
US8399632B2 (en) 2007-02-28 2013-03-19 Baxter International Inc. Method for the purification of recombinant blood coagulation factor IX enriched in sulfated and/or phosphorylated molecules
AU2008245524A1 (en) 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
EP2586788B1 (en) 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
JP5788803B2 (ja) * 2008-12-02 2015-10-07 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ポリペプチド精製
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
EP2199387A1 (en) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses for the prevention and/or the treatment of blood coagulation disorders
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
US9896677B2 (en) 2010-01-18 2018-02-20 Novo Nordisk Health Care Ag Purification of blood coagulation factors
CN103025757A (zh) * 2010-04-29 2013-04-03 巴克斯特国际有限公司 二价阳离子结合蛋白在阴离子交换树脂上的纯化方法
EP2691411B1 (en) 2011-03-29 2020-02-26 GlaxoSmithKline LLC Buffer system for protein purification
US9598687B2 (en) 2011-09-06 2017-03-21 Medimmune, Llc Methods for processing coagulation factors
PL2748179T3 (pl) * 2011-10-14 2022-04-11 Takeda Pharmaceutical Company Limited Oczyszczanie białka metodą anionowej chromatografii jonowymiennej
WO2013053888A1 (en) * 2011-10-14 2013-04-18 Baxter International Inc. Protein purification by anion exchange chromatography
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
TR201808584T4 (tr) 2013-03-15 2018-07-23 Baxalta GmbH Anyon değişimi kromotografisi aracılığıyla k vitaminine bağlı proteinler için saflaştırma yöntemi.
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
WO2017118910A1 (en) * 2016-01-07 2017-07-13 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512992A (en) * 1980-06-13 1985-04-23 Burroughs Wellcome Co. Treatment with dialkoxy pyridopyrimidine compounds
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4766224A (en) * 1985-08-19 1988-08-23 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4677196A (en) * 1985-09-06 1987-06-30 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DE3615558A1 (de) * 1986-05-09 1987-11-12 Behringwerke Ag Verfahren zur herstellung eines faktor v-konzentrats

Also Published As

Publication number Publication date
JPH02200180A (ja) 1990-08-08
IL91822A0 (en) 1990-06-10
KR900006511A (ko) 1990-05-08
DK485589D0 (da) 1989-10-03
DE68915675D1 (de) 1994-07-07
EP0363126A2 (en) 1990-04-11
US4981952A (en) 1991-01-01
EP0363126A3 (en) 1991-09-11
IE893159L (en) 1990-04-04
EP0363126B1 (en) 1994-06-01
CA1314011C (en) 1993-03-02
HU204538B (en) 1992-01-28
HUT53373A (en) 1990-10-28
DE68915675T3 (de) 2002-08-14
KR0139209B1 (ko) 1998-04-30
ES2054019T3 (es) 1994-08-01
AU635222B2 (en) 1993-03-18
DK485589A (da) 1990-04-05
ATE106406T1 (de) 1994-06-15
JP2848461B2 (ja) 1999-01-20
DK176090B1 (da) 2006-05-22
EP0363126B2 (en) 2002-03-06
IL91822A (en) 2001-06-14
DE68915675T2 (de) 1994-10-20
IE63765B1 (en) 1995-06-14
AU4251989A (en) 1990-04-12

Similar Documents

Publication Publication Date Title
ES2054019T3 (es) Procedimiento para la purificacion de proteinas dependientes de la vitamina k.
DK1075488T3 (da) Proteinoprensning ved ionbytningskromatografi
ES8801306A1 (es) Un metodo de purificar activador de plasminogeno de tejido humano
KR960007612A (ko) 재조합 사람 혈청 알부민의 정제방법
BR9606491A (pt) Processo para produção de proteina hidrofóbica em célula hospedeira e composição para produzir polipeptideo ifn-b
SG46627A1 (en) Recombinant expression vectors and purification methods for thermus thermophilus dna polymerase
ES2058538T3 (es) Compuestos de proteina a purificados y procedimiento para su preparacion.
FI103974B1 (fi) Menetelmä proteiinin puhdistamiseksi
DE3271820D1 (en) Fully synthetic cell culture medium
ATE135402T1 (de) Reinigung von erwinia-l-asparaginase
ATE166062T1 (de) Verfahren zur reinigung des big-endothelin proteins
DK286088A (da) Fremgangsmaade til adskillelse af loebekomponenter
FI863677A0 (fi) Polydispersa nativa pseudomonas-flagella(h)-antigener (fag) samt foerfarande foer framstaellning daerav.
ES2165358T3 (es) Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.
ATE76082T1 (de) Reinigungsmethode fuer antikoerper.
DK0546127T3 (da) Biosyntetisk cerebrospinalvæskekontrol og fremgangsmåde til fremstilling deraf
ATE110853T1 (de) Immuntestverfahren für zelluläres eiweiss.
Ruff et al. Glycoprotein Proteinase in Agkistrodon bilineatus Venom
DK0846166T3 (da) Fremgangsmåde til thrombinfremstilling
KR880001805A (ko) 조 임파구 인터페론의 정제방법
KR960023054A (ko) 재조합 인간 에리스로포이에틴의 정제 방법
KR920012426A (ko) 인간 표피 성장 인자의 정제방법
KR950008687A (ko) 인간 백혈구 인터페론 α-2 재조합 발현벡터 및 형질전환체
KR920012436A (ko) 인간 인슐린 유사 성장인자-i의 정제 방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 363126

Country of ref document: ES